I will begin by saying none of this is financial advice. I eat my toenails.
(10) 6/21 CALL 7.5 strike
(5) 8/15 CALL 7.5 strike
My total investment on above referenced options currently a little over $2500. IMO this is both a short term and a long term play. Time frames are 3 weeks to 3 months for the short term (what I am currently doing) and 2 year calls and/or shares for the long (what I want to be doing in my ROTH IRA).
Looks to me like IBRX consolidated since the recent drop. On April 25th , stock was a little over 5 bucks sitting right at the 50 MA. $9.07 on 5/14 was a good jump , despite not great earnings on 5/9. People took profit there. Settled to $6.50 yesterday and has been creeping up since. Today went to $7.18 before it closed at $6.84 , which happens to be right at the 50 MA again. I think I know reasons why:
ANKTIVA
Already FDA approved to treat bladder cancer. FDA really digs the drug. MULTIPLE trials ongoing for MULTIPLE other cancer types.
https://immunitybio.com/pipeline/
*Previous news of collaboration with the Serum Institute of India for manufacture. The “across all cancer types” is important.
*The 1st 1000 doses for bladder cancer shipped on 5/1 at estimates between $33k-$38.5k per dose billed to insurance companies.
https://x.com/DrPatSoonShiong/status/1785762818169684231 tweet from the doctor/CEO. That pallet is worth $33M- $38.5M dollars…
https://www.precisionvaccinations.com/vaccines/anktiva-n-803-plus-bcg-vaccine goes more in depth. States a $35.8k price tag per dose.
*IBRX released they have manufactured enough BCG for 170000 doses.
https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-completes-gmp-drug-substance-manufacturing?field_nir_news_date_value[min]= if you are doing the quick math , that is north of 5.5 BILLION DOLLARS.
Ill say that again. OVER 5.5 BILLION DOLLARS.
*There is a meeting scheduled some time in June with the FDA regarding Anktiva for non small cell lung cancer phase 2 trials. The results are good. There are a lot more trials in phase 2 as well. The FDA is paying very close attention to ANKTIVA.
https://immunitybio.com/immunitybio-announces-positive-overall-survival-results-of-anktiva-combined-with-checkpoint-inhibitors-in-non-small-cell-lung-cancer-meeting-scheduled-with-fda-to-discuss-registration-path-for-anktiv/ Definite date for FDA meeting not disclosed , but investor conference may provide insight.
*There is an investor conference scheduled for June 11th.
https://ir.immunitybio.com/company/events-and-presentations This will likely be a catalyst for the stock as they should have updated sales numbers and may have more to say regarding the FDA.
*IBRX expected earnings release 8/6
Source for this is Fidelity. Unconfirmed , but IBRX tends to announce when expected. This is where there will absolutely be concrete news on sales , if there has not been an announcement of some kind before then. I am of the opinion there will be several announcements before this date , given the multiple puzzle pieces above.
This is all I have ATM. Thanks for reading my post! I would love feedback on my ideas presented here. I think my reasoning is pretty good but I am no expert so if anyone sees anything I missed or has anything to add please comment.
Leave a Reply